<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763451</url>
  </required_header>
  <id_info>
    <org_study_id>EFC10743</org_study_id>
    <secondary_id>2008-001002-16</secondary_id>
    <nct_id>NCT00763451</nct_id>
  </id_info>
  <brief_title>GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin</brief_title>
  <acronym>GETGOAL-F1</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 in Two Titration Regimens on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in
      comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of
      treatment, followed by an extension.

      The primary objective is to assess the effects of lixisenatide when added to metformin on
      glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction when it is used in two
      steps dose titration regimen at Week 24.

      Secondary objectives are to assess the effects of lixisenatide when added to metformin on
      glycemic control in comparison to placebo in terms of HbA1c reduction when it is used in a
      one-step dose titration regimen, the percentage of patients with HbA1c less than 7 percent or
      less than or equal to 6.5%, body weight, fasting plasma glucose (FPG); to assess the safety,
      tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who complete the 24-week main double-blind treatment would undergo a variable
      double-blind extension treatment, which ends for all patients at approximately the scheduled
      date of Week 76 visit (Visit 25) for the last randomized patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Routine fasting self-measured plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG &gt;270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG &gt;240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG &gt;200 mg/dL (11.1 mmol/L) or HbA1c &gt;8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia</measure>
    <time_frame>First dose of study drug up to 3 days after the last dose administration, for up to 112 weeks</time_frame>
    <description>Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">484</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Lixisenatide (Two-Step Titration)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lixisenatide (One-Step Titration)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Two-Step Titration)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (One-Step Titration)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide (AVE0010)</intervention_name>
    <description>Self-administered by subcutaneous injections once daily within the hour preceding breakfast.</description>
    <arm_group_label>Lixisenatide (Two-Step Titration)</arm_group_label>
    <arm_group_label>Lixisenatide (One-Step Titration)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Self-administered by subcutaneous injections once daily within the hour preceding breakfast.</description>
    <arm_group_label>Placebo (Two-Step Titration)</arm_group_label>
    <arm_group_label>Placebo (One-Step Titration)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pen auto-injector</intervention_name>
    <arm_group_label>Lixisenatide (Two-Step Titration)</arm_group_label>
    <arm_group_label>Lixisenatide (One-Step Titration)</arm_group_label>
    <arm_group_label>Placebo (Two-Step Titration)</arm_group_label>
    <arm_group_label>Placebo (One-Step Titration)</arm_group_label>
    <other_name>OptiClikÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.</description>
    <arm_group_label>Lixisenatide (Two-Step Titration)</arm_group_label>
    <arm_group_label>Lixisenatide (One-Step Titration)</arm_group_label>
    <arm_group_label>Placebo (Two-Step Titration)</arm_group_label>
    <arm_group_label>Placebo (One-Step Titration)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus, diagnosed for at least 1 year at the time of screening
             visit, insufficiently controlled with metformin at a stable dose of at least 1.5
             gram/day for at least 3 months prior to screening visit

        Exclusion Criteria:

          -  HbA1c less than (&lt;) 7% or greater than (&gt;) 10% at screening

          -  At the time of screening age &lt;legal age of majority

          -  Pregnant or breastfeeding women or women of childbearing potential with no effective
             contraceptive method

          -  Type 1 diabetes mellitus

          -  Treatment with an antidiabetic pharmacological agent other than metformin within the 3
             months preceding the screening

          -  FPG at screening &gt;250 milligram per deciliter (mg/dL) (&gt;13.9 millimole per liter
             [mmol/L])

          -  Body mass index less than or equal to (&lt;)20 kilogram per square meter (kg/m^2)

          -  Weight change of more than 5 kg during the 3 months preceding the screening visit

          -  History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy,
             stomach/gastric surgery, inflammatory bowel disease

          -  History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to
             screening

          -  Hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3
             months prior to the time of screening

          -  Within the last 6 months prior to screening: history of myocardial infarction, stroke,
             or heart failure requiring hospitalization

          -  Known history of drug or alcohol abuse within 6 months prior to the time of screening

          -  Cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or
             other major systemic disease or patients with short life expectancy making
             implementation of the protocol or interpretation of the study results difficult,
             history or presence of clinically significant diabetic retinopathy, history or
             presence of macular edema likely to require laser treatment within the study period

          -  Uncontrolled or inadequately controlled hypertension at the time of screening with a
             resting supine systolic or diastolic blood pressure &gt;180 millimeter of mercury (mmHg)
             or &gt;95 mmHg, respectively

          -  Laboratory findings at the time of screening: aspartate aminotransferase (AST),
             alanine aminotransferase (ALT), or alkaline phosphatase (ALP): &gt;2 times upper limit of
             the normal (ULN) laboratory range; amylase and/or lipase: &gt;3 times ULN; total
             bilirubin: &gt;1.5 times ULN (except in case of Gilbert's syndrome); hemoglobin &lt;11
             gram/deciliter and/or neutrophils &lt;1500 per cubic millimeter (mm^3) and/or platelets
             &lt;100000/mm^3; positive test for Hepatitis B surface antigen (HBsAg) and/or Hepatitis C
             antibody (HCAb) and positive serum pregnancy test in females of childbearing potential

          -  Any clinically significant abnormality identified on physical examination, laboratory
             tests, electrocardiogram (ECG) or vital signs at the time of screening that in the
             judgment of the investigator or any sub-investigator precludes safe completion of the
             study or constrains efficacy assessment

          -  Patients who are considered by the investigator or any sub-investigator as
             inappropriate for this study for any reason (for example, impossibility to meet
             specific protocol requirements, such as scheduled visits, being able to do
             self-injections), likelihood of requiring treatment during the screening phase and
             treatment phase with drugs not permitted by the clinical study protocol; investigator
             or any sub-investigator, pharmacist, study coordinator, other study staff or relative
             thereof directly involved in the conduct of the protocol)

          -  Use of oral or injectable antidiabetic or hypoglycemic agents other than metformin
             (for example, sulfonylurea, alpha glucosidase inhibitor, thiazolidinedione,
             rimonabant, exenatide, dipeptidylpeptidase-4 (DPP-IV) inhibitor, insulin) within 3
             months prior to the time of screening

          -  Use of systemic glucocorticoids (excluding topical application or inhaled forms) for
             one week or more within 3 months prior to the time of screening

          -  Use of any investigational drug within 3 months prior to study

          -  Any previous treatment with lixisenatide or participation in any previous study with
             lixisenatide

          -  Renal impairment defined with creatinine &gt;1.4 mg/dL in women and creatinine &gt;1.5 mg/dL
             in men

          -  Clinically relevant history of gastrointestinal disease associated with prolonged
             nausea and vomiting, including, but not limited to gastroparesis and gastroesophageal
             reflux disease requiring medical treatment, within 6 months prior to the time of
             screening

          -  Allergic reaction to any glucagon like peptide-1 (GLP-1) agonist in the past (for
             example, exenatide, liraglutide) or to metacresol

          -  Additional exclusion criteria at the end of the run-in phase: informed consent
             withdrawal; lack of compliance during the single-blind placebo run-in phase (&gt;2
             injections missed); and patient with any adverse event which precludes the inclusion
             in the study, as assessed by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santafe de Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Brastislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bolli GB, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Wu Y, Hanefeld M. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med. 2014 Feb;31(2):176-84. doi: 10.1111/dme.12328. Epub 2013 Oct 24.</citation>
    <PMID>24117597</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <results_first_submitted>August 18, 2016</results_first_submitted>
  <results_first_submitted_qc>October 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 14, 2016</results_first_posted>
  <disposition_first_submitted>February 21, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>February 21, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 23, 2012</disposition_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperglycemia, GLP-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lixisenatide</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 75 centers in 15 countries between September 29, 2008 and January 27, 2011. The overall duration of treatment was at least 76 weeks (24 weeks main double-blind treatment; variable double-blind extension treatment).</recruitment_details>
      <pre_assignment_details>A total of 884 patients were screened of which 400 (45.2%) were screen failures; main reason for screen failure was glycosylated hemoglobin (HbA1c) values being out of the defined protocol range (greater than or equal to 7 percent [%] and less than or equal to 10%). A total of 484 patients were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Two-Step Titration)</title>
          <description>2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (One-Step Titration)</title>
          <description>1-step initiation regimen of volume matching placebo: 10 mcg QD subcutaneously for 2 weeks, then 20 mcg QD up to the end of treatment.</description>
        </group>
        <group group_id="P3">
          <title>Lixisenatide (Two-Step Titration)</title>
          <description>2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.</description>
        </group>
        <group group_id="P4">
          <title>Lixisenatide (One-Step Titration)</title>
          <description>1-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 2 weeks, then 20 mcg QD up to the end of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80">Randomized.</participants>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="161"/>
                <participants group_id="P4" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated/Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="79">All patients who were exposed to at least 1 dose, regardless of amount of treatment administered.</participants>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="161"/>
                <participants group_id="P4" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent-to-Treat(mITT)Population</title>
              <participants_list>
                <participants group_id="P1" count="79">All patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment.</participants>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="121"/>
                <participants group_id="P4" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor Compliance to Protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Familial and Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Site Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Two-step Titration)</title>
          <description>2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (One-step Titration)</title>
          <description>1-step initiation regimen of volume matching placebo: 10 mcg QD subcutaneously for 2 weeks, then 20 mcg QD up to the end of treatment.</description>
        </group>
        <group group_id="B3">
          <title>Lixisenatide (Two-step Titration)</title>
          <description>2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.</description>
        </group>
        <group group_id="B4">
          <title>Lixisenatide (One-step Titration)</title>
          <description>1-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 2 weeks, then 20 mcg QD up to the end of treatment.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="161"/>
            <count group_id="B4" value="161"/>
            <count group_id="B5" value="482"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" spread="8.8"/>
                    <measurement group_id="B2" value="57.5" spread="10.8"/>
                    <measurement group_id="B3" value="54.6" spread="8.9"/>
                    <measurement group_id="B4" value="55.4" spread="8.9"/>
                    <measurement group_id="B5" value="56.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Race: Caucasian/White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="141"/>
                    <measurement group_id="B5" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Asian/Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: Non Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c)</title>
          <units>percentage of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.03" spread="0.81"/>
                    <measurement group_id="B2" value="8.02" spread="0.84"/>
                    <measurement group_id="B3" value="8.10" spread="0.88"/>
                    <measurement group_id="B4" value="7.99" spread="0.87"/>
                    <measurement group_id="B5" value="8.04" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>millimole per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.60" spread="2.06"/>
                    <measurement group_id="B2" value="9.31" spread="1.82"/>
                    <measurement group_id="B3" value="9.54" spread="2.50"/>
                    <measurement group_id="B4" value="9.56" spread="2.02"/>
                    <measurement group_id="B5" value="9.52" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.45" spread="16.32"/>
                    <measurement group_id="B2" value="88.28" spread="18.43"/>
                    <measurement group_id="B3" value="87.41" spread="16.90"/>
                    <measurement group_id="B4" value="90.21" spread="18.95"/>
                    <measurement group_id="B5" value="88.50" spread="17.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.68" spread="5.33"/>
                    <measurement group_id="B2" value="5.77" spread="4.00"/>
                    <measurement group_id="B3" value="6.01" spread="4.60"/>
                    <measurement group_id="B4" value="5.77" spread="3.85"/>
                    <measurement group_id="B5" value="6.00" spread="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI was calculated by dividing body weight (kilogram) by the height (meter) squared.</description>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.38" spread="5.04"/>
                    <measurement group_id="B2" value="32.35" spread="5.86"/>
                    <measurement group_id="B3" value="32.06" spread="4.84"/>
                    <measurement group_id="B4" value="32.99" spread="5.80"/>
                    <measurement group_id="B5" value="32.47" spread="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24</title>
        <description>Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>mITT population:all randomized patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment, irrespective of compliance with study protocol/procedures. Last observation carried forward used. Number of patients analyzed=patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation regimen of volume matching placebo and 1-step initiation regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Two-Step Titration)</title>
            <description>2-step initiation regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (One-Step Titration)</title>
            <description>1-step initiation regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24</title>
          <description>Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.
The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</description>
          <population>mITT population:all randomized patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment, irrespective of compliance with study protocol/procedures. Last observation carried forward used. Number of patients analyzed=patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.</population>
          <units>percentage of hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.099"/>
                    <measurement group_id="O2" value="-0.83" spread="0.099"/>
                    <measurement group_id="O3" value="-0.92" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To detect a difference of 0.5% (or 0.4%) in absolute change from baseline in HbA1c at Week 24 between 1 lixisenatide arm and placebo (combined), 150 patients per group would provide a power of 91% (or 75%) assuming common standard deviation of 1.3% with 2-sided test at 5% significance level.
Analysis of co-variance (ANCOVA) included treatment arms, randomization strata of screening HbA1c (&lt;8.0,&gt;=8.0%) and screening BMI (&lt;30,&gt;=30 kg/m^2), country as fixed effects, baseline HbA1c as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Stepwise testing procedure applied to control type 1 error: Lixisenatide (2-step titration) was compared with Placebo (combined), if found statistically significant, then Lixisenatide (1-step titration) arm compared with Placebo (combined).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Threshold for significance at 0,05 level</method_desc>
            <param_type>Least squares (LS) mean difference</param_type>
            <param_value>-0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.089</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.583</ci_lower_limit>
            <ci_upper_limit>-0.232</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To detect a difference of 0.5% (or 0.4%) in absolute change from baseline in HbA1c at Week 24 between 1 lixisenatide arm and placebo (combined), 150 patients per group would provide a power of 91% (or 75%) assuming common standard deviation of 1.3% with 2-sided test at 5% significance level.
Analysis of co-variance (ANCOVA) included treatment arms, randomization strata of screening HbA1c (&lt;8.0,&gt;=8.0%) and screening BMI (&lt;30,&gt;=30 kg/m^2), country as fixed effects, baseline HbA1c as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Stepwise testing procedure applied to control type 1 error: Lixisenatide (2-step titration) was compared with Placebo (combined), if found statistically significant, then Lixisenatide (1-step titration) arm compared with Placebo (combined).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Threshold for significance at 0,05 level</method_desc>
            <param_type>Least squares (LS) mean difference</param_type>
            <param_value>-0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.090</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.670</ci_lower_limit>
            <ci_upper_limit>-0.317</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>mITT population. Missing data was imputed using last observation carried forward (LOCF). Here, number of patients analyzed = patients with baseline and at least 1 post-baseline FPG assessment during on-treatment period.The &quot;Placebo (Two-step Titration)&quot;and&quot;Placebo (One-step Titration)&quot;Arms/Groups were combined as pre-specified in the study protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation regimen of volume matching placebo and 1-step initiation regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Two-Step Titration)</title>
            <description>2-step initiation regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (One-Step Titration)</title>
            <description>1-step initiation regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Missing data was imputed using last observation carried forward (LOCF). Here, number of patients analyzed = patients with baseline and at least 1 post-baseline FPG assessment during on-treatment period.The &quot;Placebo (Two-step Titration)&quot;and&quot;Placebo (One-step Titration)&quot;Arms/Groups were combined as pre-specified in the study protocol</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.209"/>
                    <measurement group_id="O2" value="-0.56" spread="0.208"/>
                    <measurement group_id="O3" value="-0.53" spread="0.212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation regimen of volume matching placebo and 1-step initiation regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Two-Step Titration)</title>
            <description>2-step initiation regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (One-Step Titration)</title>
            <description>1-step initiation regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</population>
          <units>kilogram</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="0.385"/>
                    <measurement group_id="O2" value="-2.68" spread="0.385"/>
                    <measurement group_id="O3" value="-2.63" spread="0.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24</title>
        <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Week 24</time_frame>
        <population>mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation regimen of volume matching placebo and 1-step initiation regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Two-Step Titration)</title>
            <description>2-step initiation regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (One-Step Titration)</title>
            <description>1-step initiation regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24</title>
          <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="42.1"/>
                    <measurement group_id="O3" value="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24</title>
        <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Week 24</time_frame>
        <population>mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation regimen of volume matching placebo and 1-step initiation regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Two-Step Titration)</title>
            <description>2-step initiation regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (One-Step Titration)</title>
            <description>1-step initiation regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24</title>
          <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="20.4"/>
                    <measurement group_id="O3" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period</title>
        <description>Routine fasting self-measured plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG &gt;270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG &gt;240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG &gt;200 mg/dL (11.1 mmol/L) or HbA1c &gt;8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>mITT population. The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation regimen of volume matching placebo and 1-step initiation regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Two-Step Titration)</title>
            <description>2-step initiation regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (One-Step Titration)</title>
            <description>1-step initiation regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period</title>
          <description>Routine fasting self-measured plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG &gt;270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG &gt;240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG &gt;200 mg/dL (11.1 mmol/L) or HbA1c &gt;8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24</title>
        <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation regimen of volume matching placebo and 1-step initiation regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Two-Step Titration)</title>
            <description>2-step initiation regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (One-Step Titration)</title>
            <description>1-step initiation regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24</title>
          <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="25.8"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia</title>
        <description>Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.</description>
        <time_frame>First dose of study drug up to 3 days after the last dose administration, for up to 112 weeks</time_frame>
        <population>Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation regimen of volume matching placebo and 1-step initiation regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Two-Step Titration)</title>
            <description>2-step initiation regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (One-Step Titration)</title>
            <description>1-step initiation regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia</title>
          <description>Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.</description>
          <population>Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.The &quot;Placebo (Two-step Titration)&quot; and &quot;Placebo (One-step Titration)&quot; Arms/Groups were combined as pre-specified in the study protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptomatic hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe symptomatic hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug up to 3 days after the last dose administration, for up to 112 weeks</time_frame>
      <desc>Median exposure to study treatment was 567, 588 and 589 days in lixisenatide two step titration, one step titration and placebo combined arms, respectively. The analysis was performed on safety population, defined as all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Two-step Titration)</title>
          <description>2-step initiation regimen of volume matching placebo.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (One-step Titration)</title>
          <description>1-step initiation regimen of volume matching placebo.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Combined)</title>
          <description>Included all patients who received 2-step initiation regimen of volume matching placebo and 1-step initiation regimen of volume matching placebo.</description>
        </group>
        <group group_id="E4">
          <title>Lixisenatide (Two-step Titration)</title>
          <description>2-step initiation regimen of lixisenatide.</description>
        </group>
        <group group_id="E5">
          <title>Lixisenatide One-step Titration</title>
          <description>1-step initiation regimen of lixisenatide.</description>
        </group>
        <group group_id="E6">
          <title>Lixisenatide (Combined)</title>
          <description>Included all patients who received 2-step initiation regimen of lixisenatide and 1-step initiation regimen of lixisenatide.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Adams-Stokes syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood calcitonin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Pancreatic enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="119" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="101" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="220" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="108" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="50" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <description>Hypoglycaemia adverse event is based on investigator reported hypoglycaemia.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="322"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="322"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact-us@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

